Blueprint Medicines To Be Acquired By Sanofi For $9.5 Billion Including Contingent Value Rights

Goodwin Procter represented Blueprint Medicines Corporation (Nasdaq: BPMC) in its acquisition by Sanofi (NASDAQ: SNY) for an upfront payment of $129.00 per share of Blueprint common stock in cash.